Rodriguez Alfredo E, Baldi Julio, Fernández Pereira Carlos, Navia Jose, Rodriguez Alemparte Máximo, Delacasa Alejandro, Vigo Federico, Vogel Daniel, O'Neill William, Palacios Igor F
Otamendi Hospital, Buenos Aires, Argentina.
J Am Coll Cardiol. 2005 Aug 16;46(4):582-8. doi: 10.1016/j.jacc.2004.12.081.
The purpose of the present study is to report the five-year follow-up results of the ERACI II trial.
Immediate and one-year follow-up results of the ERACI II study showed a prognosis advantage of percutaneous coronary intervention (PCI) with stents over coronary artery bypass grafting (CABG).
A total of 450 patients were randomly assigned to undergo either PCI (n = 225); or CABG (n = 225). Only patients with multi-vessel disease were enrolled. Clinical follow-up during five years was obtained in 92% of the total population after hospital discharge. The primary end point of the study was to compare freedom from major adverse cardiovascular events (MACE) at 30 days, 1 year, 3 years, and 5 years of follow-up.
At five years of follow-up, patients initially treated with PCI had similar survival and freedom from non-fatal acute myocardial infarction than those initially treated with CABG (92.8% vs. 88.4% and 97.3% vs. 94% respectively, p = 0.16). Freedom from repeat revascularization procedures (PCI/CABG) was significantly lower with PCI compared with CABG (71.5% vs. 92.4%, p = 0.0002). Freedom from MACE was also significantly lower with PCI compared with CABG (65.3% vs. 76.4%; p = 0.013). At five years similar numbers of patients randomized to each revascularization procedure were asymptomatic or with class I angina.
At five years of follow-up, in the ERACI II study, there were no survival benefits from any revascularization procedure; however patients initially treated with CABG had better freedom from repeat revascularization procedures and from MACE.
本研究旨在报告ERACI II试验的五年随访结果。
ERACI II研究的即刻和一年随访结果显示,支架置入经皮冠状动脉介入治疗(PCI)较冠状动脉旁路移植术(CABG)具有预后优势。
共450例患者被随机分配接受PCI(n = 225)或CABG(n = 225)。仅纳入多支血管病变患者。出院后92%的总人群获得了五年的临床随访。研究的主要终点是比较随访30天、1年、3年和5年时主要不良心血管事件(MACE)的发生率。
在五年随访时,初始接受PCI治疗的患者与初始接受CABG治疗的患者生存率相似,非致命性急性心肌梗死发生率也相似(分别为92.8%对88.4%和97.3%对94%,p = 0.16)。与CABG相比,PCI后再次血运重建术(PCI/CABG)的发生率显著更低(71.5%对92.4%,p = 0.0002)。与CABG相比,PCI后MACE的发生率也显著更低(65.3%对76.4%;p = 0.013)。在五年时,随机接受每种血运重建术的患者中无症状或I级心绞痛的人数相似。
在ERACI II研究的五年随访中,任何血运重建术均未带来生存获益;然而,初始接受CABG治疗的患者再次血运重建术和MACE的发生率更低。